Fibromyalgia Treatment Market Regional Analysis:
APAC Market Insights
The Asia-Pacific market is anticipated to increase steadily throughout the course of the forecast period. Aspects such as the growing number of fibromyalgia patients, along with rising healthcare spending and developing healthcare infrastructure, are predicted to boost the market growth in the Asia Pacific.
North American Market Insights
North America region is likely to hold over 42.9% market share by 2035, driven by increasing prevalence and rising awareness of fibromyalgia. As per the Centers for Disease Control and Prevention, fibromyalgia affects approximately 4 million adults in the United States, accounting for approximately 2% of the adult population.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of fibromyalgia treatment is evaluated at USD 3.31 billion.
The global fibromyalgia treatment market size was worth more than USD 3.2 billion in 2025 and is poised to witness a CAGR of over 3.9%, crossing USD 4.69 billion revenue by 2035.
The North America fibromyalgia treatment market will hold over 42.9% share by 2035, driven by increasing prevalence and rising awareness of fibromyalgia.
Key players in the market include Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics.
